|
|
Résultats pour
 brevets
1.
|
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF
| Numéro d'application |
US2012039004 |
| Numéro de publication |
2013/058833 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2012-05-22 |
| Date de publication |
2013-04-25 |
| Propriétaire |
- ALEXION PHARMA HOLDING (Bermudes)
- VANDERBILT UNIVERSITY (USA)
|
| Inventeur(s) |
- Crine, Philippe
- Elefteriou, Florent
|
Abrégé
The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. Polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndromes. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes.
Classes IPC ?
- A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
- A61K 38/00 - Préparations médicinales contenant des peptides
- A61P 13/06 - Antispasmodiques
- C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
|
2.
|
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF
| Numéro d'application |
US2012060869 |
| Numéro de publication |
2013/059491 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2012-10-18 |
| Date de publication |
2013-04-25 |
| Propriétaire |
- ALEXION PHARMA HOLDING (Bermudes)
- VANDERBILT UNIVERSITY (USA)
|
| Inventeur(s) |
- Crine, Philippe
- Elefteriou, Florent
|
Abrégé
The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes, disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.
Classes IPC ?
- A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
- A61K 38/00 - Préparations médicinales contenant des peptides
- A61P 13/06 - Antispasmodiques
- C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
|
|